NCT01452451View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Conditions
Diabetes Mellitus
Interventions
DRUG

HM11260C

1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3

DRUG

Placebo

Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3

Trial Locations (1)

Unknown

Ohio City

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01452451 - Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter